1
Clinical Trials associated with GENEVAX IL-12-4532(Drexel University)A PHASE Ib PARTIALLY RANDOMIZED PILOT STUDY INTENDED TO EVALUATE THE SAFETY AND IMMUNOLOGICAL EFFECTS OF HIV-1 DNA IMMUNIZATION (PENNVAX-B) WITH OR WITHOUT CO-ADMINISTRATION OF CONSTRUCTS CONTAINING DNA ENCODING FOR THE EXPRESSION OF EITHER IL-12 OR IL-15 IN HIV INFECTED INDIVIDUALS
A phase Ib partially blinded pilot study to evaluate the safety and immunological effects of PENNVAX-B with or without co-administration of constructs containing DNA encoding for the expression of either IL-12 or IL-15.
Primary objectives
To determine the safety of HIV-1 DNA constructs (PENNVAX-B).
To determine the safety and optimal doses of the IL-12 and the IL-15 adjuvant constructs when given with PENNVAX-B.
Secondary objectives
To compare the various vaccine groups for their immunological responses to several HIV-1 antigens, utilizing the ELISPOT assay.
To analyze antibody responses to the vaccine antigens over time.
To measure CD8 cell proliferative responses to vaccine antigens over time.
100 Clinical Results associated with GENEVAX IL-12-4532(Drexel University)
100 Translational Medicine associated with GENEVAX IL-12-4532(Drexel University)
100 Patents (Medical) associated with GENEVAX IL-12-4532(Drexel University)
100 Deals associated with GENEVAX IL-12-4532(Drexel University)